Protection efficacy of the rLTB-R1 chimera against experimental swine mycoplasmal pneumonia.
Protection efficacy of the rLTB-R1 chimera against experimental swine mycoplasmal pneumonia.
Author(s): FERREIRA, M. R. A.; FINGER, P. F.; MAGALHÃES, C. G.; CUNHA, C. E. P. da; MOREIRA JÚNIOR, C.; KICH, J. D.; MORES, M. A. Z.; MOREIRA, A. N.; DELLAGOSTIN, O. A.; CONCEIÇÃO, F. R.
Summary: Abstract: Mycoplasma hyopneumoniae is the etiological agent of the Swine Mycoplasmal Pneumonia (SMP), one of the most economically significant diseases in the swine industry worldwide. Commonly used vaccines for SMP control consist of inactivated whole cells (bacterins). These vaccines are efficacious against M. hyopneumoniae challenge, but do not prevent colonization by the pathogen or completely eliminate pneumonia. P97 adhesin is conserved in the M. pneumoniae virulent strains, therefore it is an attractive target to be used in recombinant vaccines against M. hyopneumoniae. The aim of the present study was to evaluate protection afforded by rLTB-R1, a recombinant chimera composed by LTB fused with the R1 repeat region of P97 adhesin of M. hyopneumoniae, in specific-pathogen-free (SPF) piglets vaccinated by intranasal or intramuscular route and challenged with a pathogenic strain of M. hyopneumoniae.
Publication year: 2019
Types of publication: Journal article
Unit: Embrapa Swine & Poultry
Observation
Some of Embrapa's publications are published as ePub files. To read them, use or download one of the following free software options to your computer or mobile device. Android: Google Play Books; IOS: iBooks; Windows and Linux: Calibre.
Access other publications
Access the Agricultural Research Database (BDPA) to consult Embrapa's full library collection and records.
Visit Embrapa Bookstore to purchase books and other publications sold by Embrapa.